Market Cap | 331.45M | P/E | - | EPS this Y | -27.30% | Ern Qtrly Grth | - |
Income | -47.24M | Forward P/E | -5.57 | EPS next Y | -21.40% | 50D Avg Chg | -12.00% |
Sales | 850k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -28.00% |
Dividend | N/A | Price/Book | 1.89 | EPS next 5Y | - | 52W High Chg | -54.00% |
Recommedations | 1.30 | Quick Ratio | 15.38 | Shares Outstanding | 137.59M | 52W Low Chg | 45.00% |
Insider Own | 12.04% | ROA | -20.58% | Shares Float | 88.57M | Beta | 0.71 |
Inst Own | 72.08% | ROE | -30.05% | Shares Shorted/Prior | 2.30M/1.78M | Price | 2.62 |
Gross Margin | 100.00% | Profit Margin | - | Avg. Volume | 590,404 | Target Price | 7.57 |
Oper. Margin | -1,770.00% | Earnings Date | - | Volume | 286,608 | Change | -2.24% |
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Ladenburg Thalmann | Buy | Sep 16, 24 |
HC Wainwright & Co. | Buy | Aug 12, 24 |
Wedbush | Outperform | Aug 7, 24 |
HC Wainwright & Co. | Buy | Aug 6, 24 |
HC Wainwright & Co. | Buy | Jun 3, 24 |
HC Wainwright & Co. | Buy | May 16, 24 |
HC Wainwright & Co. | Buy | May 14, 24 |
HC Wainwright & Co. | Buy | Apr 16, 24 |
Wedbush | Outperform | Mar 22, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Schuetz Thomas J. | CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER | Mar 10 | Buy | 3.37 | 10,000 | 33,700 | 6,021,873 | 03/10/23 |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER | Feb 27 | Buy | 3.98 | 20,000 | 79,600 | 6,011,873 | 02/27/23 |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER | Feb 15 | Buy | 3.86 | 20,000 | 77,200 | 5,991,873 | 02/15/23 |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER | Jan 31 | Buy | 4.05 | 20,000 | 81,000 | 5,471,873 | 01/31/23 |
Bisker-Leib Vered | Chief Operating Offi.. Chief Operating Officer | Nov 22 | Sell | 4.28 | 24,500 | 104,860 | 1,060,414 | 11/25/22 |
ORBIMED ADVISORS LLC | Director Director | Nov 08 | Buy | 3.21 | 402,000 | 1,290,420 | 15,219,994 | 11/10/22 |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER | Sep 28 | Buy | 2.32 | 10,000 | 23,200 | 5,431,873 | 09/28/22 |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER | Sep 26 | Buy | 2.27 | 15,000 | 34,050 | 5,421,873 | 09/27/22 |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER | Sep 07 | Buy | 3.03 | 15,000 | 45,450 | 5,406,873 | 09/08/22 |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER | Sep 01 | Buy | 2.83 | 15,000 | 42,450 | 5,391,873 | 09/01/22 |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER | Aug 10 | Buy | 2.64 | 15,000 | 39,600 | 5,361,873 | 08/10/22 |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER | Aug 01 | Buy | 2.58 | 15,000 | 38,700 | 5,346,873 | 08/02/22 |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER | Jun 21 | Buy | 2.80 | 20,000 | 56,000 | 5,331,873 | 06/21/22 |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER | Jun 06 | Buy | 2.83 | 30,000 | 84,900 | 5,261,873 | 06/07/22 |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER | Jun 01 | Buy | 3.03 | 20,000 | 60,600 | 5,231,873 | 06/01/22 |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER | May 26 | Buy | 3.04 | 20,000 | 60,800 | 5,211,873 | 05/26/22 |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER | May 23 | Buy | 2.72 | 18,355 | 49,926 | 5,191,873 | 05/24/22 |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER | May 17 | Buy | 2.47 | 20,215 | 49,931 | 5,173,518 | 05/17/22 |
GORDON CARL L | Director Director | May 11 | Buy | 2.21 | 192,516 | 425,460 | 14,817,994 | 05/13/22 |
ORBIMED ADVISORS LLC | Director Director | May 11 | Buy | 2.21 | 192,516 | 425,460 | 14,817,994 | 05/13/22 |
ORBIMED ADVISORS LLC | Director Director | May 06 | Buy | 1.6 | 125,359 | 200,574 | 14,625,478 | 05/10/22 |
GORDON CARL L | Director Director | May 06 | Buy | 1.6 | 125,359 | 200,574 | 14,625,478 | 05/10/22 |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER | May 10 | Buy | 1.80 | 27,836 | 50,105 | 5,153,303 | 05/10/22 |
GORDON CARL L | Director Director | Nov 04 | Buy | 3.5 | 5,357,143 | 18,750,000 | 3,571,428 | 11/08/21 |
ORBIMED ADVISORS LLC | Director Director | Nov 04 | Buy | 3.5 | 5,357,143 | 18,750,000 | 3,571,428 | 11/08/21 |